MARC details
000 -LEADER |
fixed length control field |
04675nam a22004455i 4500 |
001 - CONTROL NUMBER |
control field |
978-981-19-3995-2 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240729134310.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
221020s2022 si | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9789811939952 |
-- |
978-981-19-3995-2 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJ |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED045000 |
Source |
bisacsh |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJ |
Source |
thema |
245 10 - TITLE STATEMENT |
Title |
Pulmonary Tuberculosis and Its Prevention |
250 ## - EDITION |
Edition statement |
1st ed. 2022. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Singapore : |
Name of producer, publisher, distributor, manufacturer |
Springer Nature Singapore : |
-- |
Imprint: Springer, |
Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
VIII, 294 p. 52 illus., 43 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
490 1# - SERIES TITLE |
Series statement |
Respiratory Disease Series: Diagnostic Tools and Disease Managements, |
International Standard Serial Number |
2509-5560 |
505 0# - CONTENTS |
Contents |
Part I. Epidemiology and Pathogenesis -- Chapter 1. Epidemiology -- Chapter 2. Immunology -- Chapter 3. Impact of Biologic and JAK Inhibitor Therapies on TB: How do Biologic Therapies Affect the Presentation and Treatment Course of Pulmonary TB? -- Chapter 4. Advances in Mycobacterial Laboratories: What is the latest laboratory approach to diagnose and manage pulmonary tuberculosis? -- Part II Pulmonary Tuberculosis -- Chapter 5. Advances in Diagnostics of Pulmonary tuberculosis: What is the Latest Approach to Diagnose Pulmonary TB? -- Chapter 6. HRCT diagnosis of pulmonary tuberculosis: Microlesions -- Chapter 7. Advances in Treatment of Drug Resistant Pulmonary TB: What is the latest approach to treat drug-resistant pulmonary TB? -- Chapter 8. The Role of Surgical Interventions for Pulmonary TB: What is the Role of Surgical Intervention in Pulmonary TB? -- Part III Latent TB Infection: TB Prevention -- Chapter 9. Advances in Diagnosis of Latent TB Infection: What is the Latest Approach to Diagnose Latent TB Infection to Prevent TB? -- Chapter 10. Advances in Treatment of Latent TB Infection: What is the Latest Approach to Treat Latent TB Infection to Prevent Pulmonary TB? -- Part IV Research Areas -- Chapter 11. TB vaccines: What Type of TB Vaccines are Studied and will be Available in the Future? -- Chapter 12. Clinical Trials of Pulmonary TB: Challenges and Opportunities -- Chapter 13. Contributions of Japanese Scholars to Advances in Clinical Tuberculosis Management: In TB World, What Kind of Achievements are Accomplished by Japanese Researchers?. |
520 ## - ABSTRACT |
Abstract |
Every year, 10 million people fall ill with tuberculosis (TB) in the world, and of those, 1.5 million people die even though it is a preventable and curable disease. As a result, TB remains the world's leading infectious cause of death. On the other hand, in industrialized countries, the TB incidence has fallen to a historic low, and clinicians' experience with TB diminished significantly in recent years. Additional challenges for clinicians include atypical presentation of TB in the immunocompromised, especially among the elderly, and an increasing number of patients with drug-resistant TB. Delayed diagnosis of TB leads to the spread of TB including nosocomial transmission because TB is an air-borne infectious disease, and suboptimal treatment can result in development of drug resistance. Furthermore, treatment of latent TB infection (LTBI) can prevent future TB cases but it has been under-utilized despite recent innovations in diagnosis and treatment regimens of LTBI. This bookfocuses on advances in diagnostic tools and treatment for both TB disease and latent TB infection. Each chapter/topic is written by one of the top TB experts in the field and the authors are from Japan and the US. Pulmonary Tuberculosis and its Prevention offers up-to-date information that can be incorporated into a busy practice of clinicians while they can appreciate broad international perspectives and gain in-depth knowledge on TB. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Internal medicine. |
9 (RLIN) |
6654 |
650 14 - SUBJECT HEADINGS |
Subject term |
Internal Medicine. |
9 (RLIN) |
6654 |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Saito, Takefumi. |
Relator term |
editor. |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Narita, Masahiro. |
Relator term |
editor. |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Daley, Charles L. |
Relator term |
editor. |
710 2# - ADDED CORPORATE NAME |
Added corporate author |
SpringerLink (Online service) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Respiratory Disease Series: Diagnostic Tools and Disease Managements, |
International Standard Serial Number |
2509-5560 |
856 ## - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="#gotoholdings">#gotoholdings</a> |
Link text |
Access resource |
245 ## - TITLE STATEMENT |
Medium |
[E-Book] |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
912 ## - |
-- |
ZDB-2-SME |
912 ## - |
-- |
ZDB-2-SXM |